Franck Poitiers

Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans

Gissette Reyes‐Soffer, Marianna Pavlyha, Colleen Ngai et al. · Circulation · 2016 · 230 citations · Full text

Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin

Christoph Kapitza, Thomas Först, Hans Veit Coester et al. · Diabetes Obesity and Metabolism · 2013 · 189 citations · Full text

Pharmacokinetic assessment of a five‐probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A

Sandrine Turpault, William R. Brian, Robert Van Horn et al. · British Journal of Clinical Pharmacology · 2009 · 145 citations · Full text

In Elderly Women Weight is the Best Predictor of a Very Low Bone Mineral Density: Evidence from the EPIDOS Study

Patricia Dargent‐Molina, Franck Poitiers, Gérard Bréart · Osteoporosis International · 2000 · 113 citations

Obesity, Bone Disease, Bone Health +11

A Randomized Study of the Relative Pharmacokinetics, Pharmacodynamics, and Safety of Alirocumab, a Fully Human Monoclonal Antibody to <scp>PCSK</scp>9, After Single Subcutaneous Administration at Three Different Injection Sites in Healthy Subjects

Catherine Lunven, Tobias Paehler, Franck Poitiers et al. · Cardiovascular Therapeutics · 2014 · 57 citations · Full text